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The letters from Nanra and Lornoy et al claim that
the incidence of analgesic nephropathy (AN) would be
To the Editor: The article in the December 2000 issue controlled not by an isolated phenacetin withdrawal, but
of Kidney International by the Ad Hoc Committee of the by a ban on all combined analgesics. Nanra’s conclusion,
International Study Group on Analgesics and Nephropa- however, was based on short-term observations in a lim-
thy [1] questions the harmful impact of nonphenacetin- ited number of patients [1]. In Australia, phenacetin
containing analgesic mixtures on the kidneys. We won- was progressively withdrawn from the abused brands of
der whether there is a need for these combinations at
analgesics, and its sale was legally prohibited in 1977.all. APC brands have never been proven to be effective
Two years later, the sales of all combined analgesicsfor the indication of chronic pain treatment. The intro-
were also restricted. Because the renal consequences ofduction of these formulations is based on an irrational
phenacetin may not occur until many years after intakeguiding principle presented by Buergi in 1927 (references
has ceased, the limited follow-up after phenacetin with-in [2]). The German view is (1) almost none of the single
drawal alone does not allow its effects to be separatedanalgesics (not even phenacetin) have been taken regu-
from those of the later withdrawal of combined analge-larly in amounts reached by mixed compounds; and (2)
since over-the-counter analgesic compounds have never sics. Theoretical speculations, such as those about the
been sold without caffeine (20 to 50 mg per unit) and toxicity of paracetamol, can only suggest hypotheses. All
since low-dose caffeine alone is not effective for pain the proposed hypotheses, however, should be (but have
relief (with the exception of caffeine-withdrawal–induced not been) compatible with the evidence that the incidence
headache), why is it still used? of AN decreased similarly, in both Belgium and Australia,
Our study provides evidence that, besides phenacetin, despite persistently high consumption of mixed non-
paracetamol-containing mixtures do increase the risk of
phenacetin analgesics in Belgium [2, 3].end-stage renal disease [3]. Because risk estimates are
Lornoy et al state that the incidence of AN in their di-based on hospital controls, the specific risks for the gen-
alysis unit correlated better with the withdrawal of non-eral population may be even higher. Detrimental renal
phenacetin analgesics than with the withdrawal of phen-effects of high-dose paracetamol exposure are well docu-
acetin. Because AN is not evenly distributed by geographicmented in both clinical and experimental studies [sum-
region, however, local incidence data are influenced bymarized in 4, 5].
Warnings about the adverse effects of phenacetin changes in recruitment of patients for dialysis due to a
and nonphenacetin-containing compounds have been changing pattern of referral by local nephrologists and/or
ignored for a long time [6]. The debate continues, why to the opening of new regional dialysis units. The data
and for what? in the figure by Lornoy et al do not show the expected
progressive increase in the total number of patients ad-Wolfgang Pommer and Eberhard Greiser
Berlin, Germany mitted for dialysis and are most consistent with a change
